



SJ0043

LRB101 11737 MST 58399 r

1 SENATE JOINT RESOLUTION

2 WHEREAS, The human papillomavirus (HPV) is the most common  
3 sexually transmitted virus in the United States; nearly 14  
4 million people become infected each year; and

5 WHEREAS, HPV causes approximately 33,700 cases of  
6 HPV-associated cancers each year, including cervical, anal,  
7 and oropharyngeal cancers; and

8 WHEREAS, The 9-valent HPV vaccine protects against nine  
9 types of HPV infection; and

10 WHEREAS, Within six years of vaccine introduction in 2006,  
11 there was a 64% decrease in HPV in women ages 14 to 19 years,  
12 and 34% among females ages 20 to 24 years; and

13 WHEREAS, The HPV vaccine was thoroughly tested for safety  
14 before being licensed and released and continues to be  
15 monitored by the Centers for Disease Control and Prevention and  
16 the Food and Drug Administration; and

17 WHEREAS, There have been no serious safety concerns linked  
18 to the vaccine; and

19 WHEREAS, The American Academy of Pediatrics and the

1 Advisory Committee on Immunization Practices recommend two  
2 doses of the HPV vaccine for males and females ages 11-12; the  
3 vaccine is approved for men and women through age 45; and

4 WHEREAS, in Illinois, only 50 percent of males and females  
5 ages 13 to 17 years were up to date on HPV vaccination in 2017;  
6 therefore, be it

7 RESOLVED, BY THE SENATE OF THE ONE HUNDRED FIRST GENERAL  
8 ASSEMBLY OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES  
9 CONCURRING HEREIN, that we encourage adolescents in Illinois to  
10 receive the HPV vaccine to protect themselves against HPV  
11 infection and HPV-related cancers.